About five years ago, former Teva Pharmaceutical CEO Jeremy Levin launched Ovid Therapeutics with a plan to develop treatments for rare brain diseases.
Now, with the completion of a clinical trial on the horizon anticipated to provide enough data to file... Read more »
Rodin Therapeutics has limited data from human studies about its neurodegeneration drug, but the company’s new approach to treating brain disorders has proven attractive enough for Alkermes to plunk down $100 million to buy the startup.
According to financial terms announced... Read more »
A resTORbio respiratory drug has failed a late-stage test, and the company is stopping further development of the compound for lung infections in elderly patients.
In the first of two Phase 3 studies, ResTORbio on Friday released preliminary data showing that... Read more »
Lung injuries connected to the use of electronic cigarettes have topped 2,000 and killed 40 people, according to the Centers for Disease Control and Prevention.
It’s still unclear whether the cases are tied to legally sold products or devices modified by... Read more »
The list of activities our smartphones can control grows daily. Transfer money? It’s simple. Order groceries? That, too. Turn off the bedroom lights? Check.
How about contraception?
Advancing new forms of birth control is a central focus at Daré Bioscience (NASDAQ:... Read more »
Launched just last year, artificial intelligence-powered drug discovery company X-37 now has raised $14.5 million in Series A financing to expand its development programs.
Co-founded by Atomwise and a team from Velocity Pharmaceutical Development, the San Francisco, CA-based company uses Atomwise’s... Read more »
[Updated, 12:15 p.m. See below.] Inside of a cell, some proteins and RNA are concentrated in liquid droplets that assemble in formation during a variety of cellular functions. Dewpoint Therapeutics is making headway understanding the role these droplets play... Read more »
The FDA has stopped a clinical trial testing a Solid Biosciences gene therapy for Duchenne muscular dystrophy after a patient developed complications associated with the experimental treatment.
Cambridge, MA-based Solid Bio says the problems deemed to be related to the gene... Read more »
A Roche drug in development as a treatment for spinal muscular atrophy achieved the main goals of a key study, helping to build the case that the drug could challenge a Biogen therapy already approved for the rare disorder.
Roche announced... Read more »
These are heady times for neuroscience research. Startups developing new approaches to brain disorders are raising money to advance their discoveries toward clinical trials. One failed neuro drug is getting another shot.
On Nov. 19 in San Francisco, we’ll... Read more »
[Updated 6:41 p.m. See below.] A drug that Celgene and Acceleron Pharma developed to treat low red blood cell levels in patients who have a rare blood disorder now has regulatory clearance to enter the market.
The FDA on... Read more »
During the state of the union address this year, President Trump pledged to end HIV transmission within the next decade. A key part of that plan is an HIV prevention drug made by Gilead Sciences. That drug has now become the... Read more »
Biotech startup eGenesis, which is applying gene editing to animal organs in order to make them suitable for human transplant, has raised $100 million to ramp up work on its kidney program and bring it into human testing.
The Series B... Read more »